فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
The Ministry of Health and Social Protection has announced significant reductions in the prices of cancer treatment medications, aimed at facilitating patients’ access to essential treatments, especially for women, at lower costs. The ministerial decision, published in the official gazette (issue 7392), includes price reductions for 10 types of medications, with values ranging from 10 dirhams to over 6,000 dirhams in some cases, depending on the type of medication and its previous cost.
Among the most prominent drugs included in these reductions is IRESSA 250 mg, whose price dropped from 16,063 dirhams to 9,355 dirhams, a reduction of 6,700 dirhams. The price of Faslodex 250 mg, used in the treatment of breast cancer in women, was also reduced from 3,732 dirhams to 2,893 dirhams, with a discount of 839 dirhams.
In addition, the price of CAELYX PEGYLATED LIPOSOMAL 2mg, used for treating specific cancer tumors, was reduced from 3,907 dirhams to 3,727 dirhams, which is the same price used for hospitals.
The ministerial decision also set new prices for a number of original medications, such as ROZLYTREK 200 mg, priced at 46,408 dirhams for the public and 45,895 dirhams for hospitals, and RYBREVANT 350 mg, with a price set at 15,290 dirhams.
Furthermore, 42 new generic drugs were approved, following the approval and pricing requests received by the ministry from pharmaceutical companies.
This decision is part of the government’s efforts to reduce treatment costs and improve access to essential medications, especially in light of the significant financial burdens facing families, particularly given the rising costs of treatments for chronic and serious diseases such as cancer.
Source: Fes News Media
